Second Sight Medical Products (EYES) Getting Somewhat Favorable Media Coverage, Analysis Shows

Press coverage about Second Sight Medical Products (NASDAQ:EYES) has trended somewhat positive on Sunday, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Second Sight Medical Products earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave news coverage about the medical device company an impact score of 43.978389619275 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Shares of Second Sight Medical Products (NASDAQ EYES) opened at $2.02 on Friday. The company has a market cap of $114.75, a PE ratio of -3.16 and a beta of 3.71. Second Sight Medical Products has a one year low of $0.90 and a one year high of $2.83.

Second Sight Medical Products (NASDAQ:EYES) last released its earnings results on Thursday, November 2nd. The medical device company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02. The business had revenue of $1.61 million during the quarter, compared to analysts’ expectations of $1.54 million. Second Sight Medical Products had a negative net margin of 565.12% and a negative return on equity of 184.87%. analysts anticipate that Second Sight Medical Products will post -0.55 earnings per share for the current fiscal year.

A number of research firms have recently commented on EYES. Zacks Investment Research raised shares of Second Sight Medical Products from a “sell” rating to a “hold” rating in a research note on Monday, January 8th. HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Second Sight Medical Products in a research note on Monday, November 6th.

WARNING: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at

Second Sight Medical Products Company Profile

Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.

Insider Buying and Selling by Quarter for Second Sight Medical Products (NASDAQ:EYES)

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with's FREE daily email newsletter.

Leave a Reply